Time-lag bias in trials of pediatric antidepressants: A systematic review and meta-analysis

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 50, Issue 1, 2011, Pages 63-72

  Reyes, Magdalena M ^a   Panza, Kaitlyn E ^a   Martin, Andrs ^a   Bloch, Michael H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antidepressant agents; child and adolescent psychiatry; meta analysis; publication bias; serotonin reuptake inhibitors

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; MAJOR DEPRESSION; MEDICAL LITERATURE; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLISHING; SENSITIVITY ANALYSIS; STANDARD; SYSTEMATIC REVIEW; TIME LAG BIAS;

ADOLESCENT; CHILD; CHILD PSYCHIATRY; DEPRESSIVE DISORDER, MAJOR; DRUG COSTS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PUBLICATION BIAS; PUBLISHING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78650169395     PISSN: 08908567     EISSN: 15275418     Source Type: Journal    
DOI: 10.1016/j.jaac.2010.10.008     Document Type: Article

References (39)

1. K. Dickersin, C.M. Olson, and D. Rennie Association between time interval to publication and statistical significance JAMA 287 2002 2829 2831
2. R.W. Scherer, P. Langenberg, and E. von Elm Full publication of results initially presented in abstracts Cochrane Database Syst Rev 2007 MR000005
3. K. Dickersin, Y.I. Min, and C.L. Meinert Factors influencing publication of research results Follow-up of applications submitted to two institutional review boards JAMA 267 1992 374 378
4. E.H. Turner, A.M. Matthews, E. Linardatos, R.A. Tell, and R. Rosenthal Selective publication of antidepressant trials and its influence on apparent efficacy N Engl J Med 358 2008 252 260
5. C.J. Whittington, T. Kendall, P. Fonagy, D. Cottrell, A. Cotgrove, and E. Boddington Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data Lancet 363 2004 1341 1345
6. J.A. Bridge, S. Iyengar, and C.B. Salary Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials JAMA 297 2007 1683 1696
7. S. Hopewell, K. Loudon, M.J. Clarke, A.D. Oxman, and K. Dickersin Publication bias in clinical trials due to statistical significance or direction of trial results Cochrane Database Syst Rev 2009 MR000006
8. S. Hopewell, M. Clarke, L. Stewart, and J. Tierney Time to publication for results of clinical trials Cochrane Database Syst Rev 2007 MR000011
9. J.P. Ioannidis Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials JAMA 279 1998 281 286
10. M.K. Krzyzanowska, M. Pintilie, and I.F. Tannock Factors associated with failure to publish large randomized trials presented at an oncology meeting JAMA 290 2003 495 501
11. G. Dubitsky Review and Evaluation of Clinical Data: Placebo-Controlled Antidepressant Studies in Pediatric Patients http://www.fda.gov/ohrms/DOCKETS/ ac/04/briefing/2004-4065b1-08-TAB06-Dubitsky-Review.pdf 2004 Accessed August 6, 2004
12. Review Manager (RevMan) [computer program] Version 5.0 for Windows 2003 Nordic Cochrane Centre, Cochrane Collaboration Copenhagen
13. Higgins J, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. In: The Cochrane Library, 2006, Issue 4. Chichester, UK: Wiley.
14. M. Egger, G. Davey Smith, M. Schneider, and C. Minder Bias in meta-analysis detected by a simple, graphical test Br Med J 315 1997 629 634
15. R. Churchill, V. Hunot, and R. Corney A systematic review of controlled trials of the effectiveness and cost effectiveness of brief psychological treatments for depression Health Technol Assess 5 2001
16. B.M. Althouse, J.D. West, C.T. Bergstrom, and T. Bergstrom Differences in impact factor across fields and over time J Am Soc Inform Sci Technol 60 2009 27 34
17. K.D. Wagner, A.S. Robb, R.L. Findling, J. Jin, M.M. Gutierrez, and W.E. Heydorn A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents Am J Psychiatry 161 2004 1079 1083
18. K.D. Wagner, J. Jonas, R.L. Findling, D. Ventura, and K. Saikali A double-blind, randomized, placebo-controlled trial of escitalopram in the treatment of pediatric depression J Am Acad Child Adolesc Psychiatry 45 2006 280 288
19. K.D. Wagner, P. Ambrosini, and M. Rynn Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials JAMA 290 2003 1033 1041
20. A.L. von Knorring, G.I. Olsson, P.H. Thomsen, O.M. Lemming, and A. Hulten A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder J Clin Psychopharmacol 26 2006 311 315
21. J. March, S. Silva, and S. Petrycki Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial JAMA 292 2004 807 820 (Pubitemid 39079667)
22. M.B. Keller, N.D. Ryan, and M. Strober Efficacy of paroxetine in the treatment of adolescent major depression: a randomized, controlled trial J Am Acad Child Adolesc Psychiatry 40 2001 762 772
23. G.J. Emslie, K.D. Wagner, and S. Kutcher Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial J Am Acad Child Adolesc Psychiatry 45 2006 709 719
24. G.J. Emslie, D. Ventura, A. Korotzer, and S. Tourkodimitris Escitalopram in the treatment of adolescent depression: a randomized placebo-controlled multisite trial J Am Acad Child Adolesc Psychiatry 48 2009 721 729
25. G.J. Emslie, A.J. Rush, and W.A. Weinberg A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression Arch Gen Psychiatry 54 1997 1031 1037
26. G.J. Emslie, J.H. Heiligenstein, and K.D. Wagner Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial J Am Acad Child Adolesc Psychiatry 41 2002 1205 1215
27. G.J. Emslie, R.L. Findling, P.P. Yeung, N.R. Kunz, and Y. Li Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials J Am Acad Child Adolesc Psychiatry 46 2007 479 488
28. R. Berard, R. Fong, D.J. Carpenter, C. Thomason, and C. Wilkinson An international, multicenter, placebo-controlled trial of paroxetine in adolescents with major depressive disorder J Child Adolesc Psychopharmacol 16 2006 59 75
29. J.G. Simeon, V.F. Dinicola, H.B. Ferguson, and W. Copping Adolescent depression: a placebo-controlled fluoxetine treatment study and follow-up Prog Neuropsychopharmacol Biol Psychiatry 14 1990 791 795
30. S. Hetrick, S. Merry, J. McKenzie, P. Sindahl, and M. Proctor Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents Cochrane Database Syst Rev 2007 CD004851
31. MHRA. Medicines and Healthcare Products Regulatory Agency (MHRA) Selective Serotonin Reuptake Inhibitors (SSRIs): Overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data http://www.mhra.gov.uk/CON019494 Accessed September 5, 2009
32. J. Lexchin, L.A. Bero, B. Djulbegovic, and O. Clark Pharmaceutical industry sponsorship and research outcome and quality: systematic review Br Med J 326 2003 1167 1170
33. H. Ulas, T. Binbay, and K. Alptekin Financial conflict of interest in clinical psychiatry studies: a review Turk Psikiyatri Derg 19 2008 418 426
34. FDA Food and Drug Administration Amendments Act (FDAAA) of 2007 http://www.fda.gov/RegulatoryInformation/Legislation/ FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/ FoodandDrugAdminstrationAmendmentsActof2007/default.htm?sms-ss=email&at-xt= 4cdef5270f914015,0 2007 Accessed January 4, 2010
35. L. Hirsch Trial registration and results disclosure: impact of US legislation on sponsors, investigators, and medical journal editors Curr Med Res Opin 24 2008 1683 1689
36. S. Mathieu, I. Boutron, D. Moher, D.G. Altman, and P. Ravaud Comparison of registered and published primary outcomes in randomized controlled trials JAMA 302 2009 977 984
37. E.H. Turner Closing a loophole in the FDA Amendments Act Science 322 2008 44 46
38. M.C. Zanarini, and F.R. Frankenburg Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study Am J Psychiatry 160 2003 167 169
39. J.A. Bridge, B. Birmaher, S. Iyengar, R.P. Barbe, and D.A. Brent Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder Am J Psychiatry 166 2009 42 49